high cholesterol and glp-1 Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update Understanding GLP-1 receptor agonists and

Additionally, Retatrutide causes significant weight loss while metformin is weight-neutral or causes modest weight loss

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

Start by reviewing your Aetna drug formulary or speaking with your healthcare provider to find the best next step for your health and budget

Phase 2 trials in people with diabetes showed HbA1c reductions of 1.3-2.0% along with significant weight loss